Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANT CHAWLA

NPI
1508868837
CMS profile
249452
Location
SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$7,202.88

94 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $2,767.50 1
Food and Beverage $2,385.43 91
Consulting Fee $1,950.00 1
Education $99.95 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANT CHAWLA

NPI 1508868837 · CMS profile ID 249452

SANTA MONICA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508868837?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANT CHAWLA, NPI 1508868837, CMS profile ID 249452. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508868837?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SANT CHAWLA, NPI 1508868837, CMS profile ID 249452. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508868837?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SANT CHAWLA, NPI 1508868837, CMS profile ID 249452, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–94 of 94 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1508868837?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

94 matching records · $7,202.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 94 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–94 of 94.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Coherus Biosciences Inc. $23.4906/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956561701 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.3806/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887443971 CMS
Foundation Medicine, Inc. $229.0006/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924041967 CMS
E.R. Squibb & Sons, L.L.C. $18.6406/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952471 CMS
Seagen Inc. $29.4606/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904136695 CMS
Dendreon Pharmaceuticals LLC $24.6805/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943097877 CMS
GE HealthCare $24.4505/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 953433479 CMS
Kite Pharma, Inc. $17.4305/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920056075 CMS
Karyopharm Therapeutics Inc. $33.2905/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946528661 CMS
GENZYME CORPORATION $29.6105/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938761407 CMS
Mylan Institutional Inc. $24.3205/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963952645 CMS
Blueprint Medicines Corporation $25.4805/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958932821 CMS
Incyte Corporation $26.9605/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942994685 CMS
Merck Sharp & Dohme LLC $21.7605/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944155025 CMS
Incyte Corporation $99.9504/29/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942994691 CMS
Seagen Inc. $27.9104/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904136667 CMS
Coherus Biosciences Inc. $24.2204/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956561693 CMS
Amgen Inc. $25.9604/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939886465 CMS
E.R. Squibb & Sons, L.L.C. $20.6704/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952457 CMS
E.R. Squibb & Sons, L.L.C. $19.0003/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952459 CMS
E.R. Squibb & Sons, L.L.C. $125.0003/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952487 CMS
Lilly USA, LLC $26.5203/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918343169 CMS
Coherus Biosciences Inc. $25.6003/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 956561681 CMS
PFIZER INC. $20.3203/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949087941 CMS
G1 Therapeutics, Inc. $23.4103/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954028963 CMS
Novartis Pharmaceuticals Corporation $17.0303/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893566483 CMS
Incyte Corporation $22.0803/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942994651 CMS
Incyte Corporation $23.8503/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942994535 CMS
Novartis Pharmaceuticals Corporation $24.9002/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893566481 CMS
E.R. Squibb & Sons, L.L.C. $22.3802/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952445 CMS
Incyte Corporation $21.6702/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942994511 CMS
Epizyme, Inc., $18.5802/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917606635 CMS
Kite Pharma, Inc. $21.3302/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920056177 CMS
E.R. Squibb & Sons, L.L.C. $15.0302/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952449 CMS
E.R. Squibb & Sons, L.L.C. $7.0302/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952451 CMS
Novartis Pharmaceuticals Corporation $16.3101/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893566479 CMS
Merck Sharp & Dohme LLC $22.3801/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944068319 CMS
E.R. Squibb & Sons, L.L.C. $7.4201/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952437 CMS
E.R. Squibb & Sons, L.L.C. $1.1601/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952439 CMS
E.R. Squibb & Sons, L.L.C. $7.0301/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952441 CMS
E.R. Squibb & Sons, L.L.C. $21.7401/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932952447 CMS
AstraZeneca Pharmaceuticals LP $18.0001/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920235595 CMS
Kite Pharma, Inc. $23.5701/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920056039 CMS
Seagen Inc. $24.5501/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904136633 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,309.59 99
PY2020 $7,871.07 51
PY2021 $4,759.63 100
PY2022 $7,202.88 94
PY2023 $3,164.46 110
PY2024 $2,318.18 67
PY2025 $3,030.14 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $6,400.00 2
PY2025 Principal investigator $929,442.37 100
PY2024 Principal investigator $1,238,832.99 89
PY2023 Recipient $1,270.00 2
PY2023 Principal investigator $1,388,882.22 78
PY2022 Recipient $940.00 1
PY2022 Principal investigator $1,019,395.82 42
PY2021 Recipient $388.51 2
PY2021 Principal investigator $455,963.10 30
PY2020 Recipient $2,460.36 4
PY2020 Principal investigator $2,128,468.11 53
PY2019 Principal investigator $3,640,139.13 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

102 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $46,130.90 12/18/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812338
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,195.00 12/18/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812354
Principal investigator 1 Merck Sharp & Dohme LLC $157,320.00 12/18/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A P1,2 dose escal,expan to evaluate PYX-201 and Pembro in Adv solid tumors No dispute reported 06/30/2026 1232936250
Principal investigator 1 Epizyme, Inc. $45,961.00 10/31/2025 Non-covered Recipient Entity
Oncology Center
A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma No dispute reported 06/30/2026 1184282387
Principal investigator 1 Epizyme, Inc. $45,961.00 10/31/2025 Non-covered Recipient Entity
Oncology Center
A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma No dispute reported 06/30/2026 1184282389
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,567.00 10/03/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250209069
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $1,899.00 10/03/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250209071
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $624.00 10/03/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250209073
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,988.90 08/07/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812398
Principal investigator 1 Servier BioInnovation $15,000.00 08/06/2025 Non-covered Recipient Entity
Sarcoma Oncology Research Center
Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study) No dispute reported 06/30/2026 1235974000
Principal investigator 1 Servier BioInnovation $2,000.00 08/06/2025 Non-covered Recipient Entity
Sarcoma Oncology Research Center
Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 systemic treatment regimen (CHONQUER study) No dispute reported 06/30/2026 1235974004
Recipient PFIZER INC. $3,200.00 08/01/2025 Covered Recipient Physician ONTORPACEPT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228803504
Recipient PFIZER INC. $3,200.00 08/01/2025 Covered Recipient Physician ONTORPACEPT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228803508
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,307.99 07/15/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812330
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,581.10 07/15/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812332
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,717.40 07/15/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812334
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,108.00 07/15/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812336
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,761.90 07/08/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812396
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,168.00 07/01/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812352
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,205.90 06/26/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812328
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,806.00 06/16/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812326
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,893.40 06/16/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812350
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,940.40 06/12/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812394
Principal investigator 1 Amgen Inc. $1,488.58 05/27/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER LLC
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death-1 (PD-1) Antibody, in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 1246648039
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $2,400.00 05/23/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208919
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,096.00 05/16/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812318
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,644.00 05/16/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812320
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,128.00 05/16/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812322
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,096.00 05/16/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812324
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,547.50 05/15/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812348
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,346.00 05/15/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812390
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $37,038.00 05/15/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812392
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $54,982.00 05/14/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812388
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,195.80 05/13/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812316
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,692.00 05/13/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812382
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,865.00 05/13/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812384
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $37,038.00 05/13/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812386
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $588.00 05/09/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208921
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $140.00 05/09/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250209023
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $395.00 05/09/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250209025
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $4,873.00 05/09/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250209027
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $588.00 05/09/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250209029
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,336.50 05/09/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812314
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,336.50 05/09/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812346
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,345.30 05/09/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812380
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,173.00 05/07/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812366
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $49,384.00 05/07/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812368
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,004.75 05/07/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812370
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,173.00 05/07/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812372
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,173.00 05/07/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812374
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,173.00 05/07/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812376
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,865.00 05/07/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812378
Principal investigator 1 Amgen Inc. $27,017.00 05/02/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER LLC
A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors No dispute reported 06/30/2026 1246648043
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,786.80 05/02/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812344
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,821.50 04/14/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812364
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,243.00 04/10/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812310
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,692.00 04/09/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812362
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,009.50 04/01/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812306
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,261.80 04/01/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812308
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30.09 04/01/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812312
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250207864
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250207866
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250207868
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250207870
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250207882
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250207884
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250207886
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250207888
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208925
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208927
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208929
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208931
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208933
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208935
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208937
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208939
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208941
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208943
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208945
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208969
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208971
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208973
Principal investigator 1 ADC THERAPEUTICS AMERICA, INC. $437.50 03/28/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
Not supplied No dispute reported 06/30/2026 1250208975
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,764.00 03/26/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812304
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28,066.50 03/26/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812360
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,346.00 03/24/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812342
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $14,446.80 03/18/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812358
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,622.39 03/11/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812302
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,394.50 03/04/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812300
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,706.67 03/03/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812296
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $612.10 03/03/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812298
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30.09 03/01/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812288
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $537.54 03/01/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812294
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,687.25 03/01/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812340
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,807.54 02/26/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812292
Principal investigator 1 SpringWorks Therapeutics, Inc. $11,943.50 02/20/2025 Non-covered Recipient Entity
SARCOMA ONCOLOGY RESEARCH CENTER
NIR-DT-301 No dispute reported 06/30/2026 1232168422
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,719.00 02/07/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812282
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30.09 02/01/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812286
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,078.30 01/22/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4 No dispute reported 06/30/2026 1220812280
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,961.60 01/06/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812284
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,492.40 01/06/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of BI 907828 (Brigimadlin) treatment in patients with advanced treatment-naive or pre-treated dedifferentiated liposarcoma No dispute reported 06/30/2026 1220812356
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30.09 01/01/2025 Non-covered Recipient Entity
Sarcoma Oncology Center
A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (brigimadlin) in patients with advanced or metastatic solid tumors No dispute reported 06/30/2026 1220812290